LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Kodu・Aktsiate loetelu・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Suletud

SektorTervishoid

21.62 -1.86

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

21.49

Max

21.77

Põhinäitajad
By Trading Economics
Sissetulek	258M 216M
Müük	280M 459M
P/E Sektori keskmine	65.229 121.746
Aktsiakasum	1.67
Kasumimarginaal	47.04
Töötajad	705
EBITDA	258M 228M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+43.72% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	24. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-872M 2.9B
Eelmine avamishind	23.48
Eelmine sulgemishind	21.62

Uudiste sentiment

By Acuity

19%

81%

21 / 351 Pingereas Healthcare

Apellis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. veebr 2026, 23:21 UTC

Omandamised, ülevõtmised, äriostud

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15. veebr 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15. veebr 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15. veebr 2026, 23:06 UTC

Tulu

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15. veebr 2026, 23:04 UTC

Tulu

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15. veebr 2026, 23:04 UTC

Tulu

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15. veebr 2026, 23:01 UTC

Tulu

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15. veebr 2026, 23:01 UTC

Tulu

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15. veebr 2026, 22:52 UTC

Omandamised, ülevõtmised, äriostud

Qube Shareholders to Receive A$5.20/Share in Cash

15. veebr 2026, 22:52 UTC

Omandamised, ülevõtmised, äriostud

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO Tania Archibald Speaking on a Call With Media

15. veebr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15. veebr 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15. veebr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15. veebr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15. veebr 2026, 20:48 UTC

Tulu

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15. veebr 2026, 20:47 UTC

Tulu

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15. veebr 2026, 20:46 UTC

Tulu

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15. veebr 2026, 20:45 UTC

Tulu

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15. veebr 2026, 20:44 UTC

Tulu

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15. veebr 2026, 20:44 UTC

Tulu

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15. veebr 2026, 20:43 UTC

Tulu

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15. veebr 2026, 20:42 UTC

Tulu

BlueScope Net Debt A$2.2 Million at Dec. 31

15. veebr 2026, 20:42 UTC

Tulu

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15. veebr 2026, 20:41 UTC

Tulu

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15. veebr 2026, 20:40 UTC

Tulu

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15. veebr 2026, 20:40 UTC

Tulu

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15. veebr 2026, 20:39 UTC

Tulu

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Võrdlus sarnastega

Hinnamuutus

Apellis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

43.72% tõus

12 kuu keskmine prognoos

Keskmine 31.69 USD 43.72%

Kõrge 48 USD

Madal 19 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Apellis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Apellis Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

21 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.